Ankh Life Sciences Limited

27 patents currently held · Updated Nov 15, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Oct 2030

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due May 12, 2027
The maintenance fee for Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof (US 10,471,049) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
1 fee due Jun 17, 2027
The maintenance fee for Therapeutics compositions containing harmine and isovanillin components, and methods of use thereof (US 10,507,200) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
1 fee due Jul 14, 2027
The maintenance fee for Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof (US 10,532,043) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
1 fee due Sep 3, 2027
The maintenance fee for Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof (US 10,576,067) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
1 fee due Oct 9, 2027
The maintenance fee for Methods for treating plasma cell neoplasm with human therapeutic agents (US 11,951,099) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 8,039,025	Methods and dosage forms for the treatment of human cancers In force Ends no later than Oct 15, 2030 · From the USPTO record	In force	Ends no later than Oct 15, 2030	From the USPTO record
US 9,402,834	Human therapeutic agents In force Ends no later than May 26, 2035 · From the USPTO record	In force	Ends no later than May 26, 2035	From the USPTO record
US 9,907,786	Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof In force Ends no later than May 26, 2035 · From the USPTO record	In force	Ends no later than May 26, 2035	From the USPTO record
US 10,092,550	Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof In force Ends no later than May 26, 2035 · From the USPTO record	In force	Ends no later than May 26, 2035	From the USPTO record
US 10,471,049	Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof In force Ends no later than May 26, 2035 · From the USPTO record	In force	Ends no later than May 26, 2035	From the USPTO record
US 10,507,200	Therapeutics compositions containing harmine and isovanillin components, and methods of use thereof In force Ends no later than May 26, 2035 · From the USPTO record	In force	Ends no later than May 26, 2035	From the USPTO record
US 10,532,043	Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof In force Ends no later than May 26, 2035 · From the USPTO record	In force	Ends no later than May 26, 2035	From the USPTO record
US 10,576,067	Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof In force Ends no later than May 26, 2035 · From the USPTO record	In force	Ends no later than May 26, 2035	From the USPTO record
US 10,744,124	Human therapeutic agents In force Ends no later than May 26, 2035 · From the USPTO record	In force	Ends no later than May 26, 2035	From the USPTO record
US 10,751,330	Human therapeutic agents In force Ends no later than May 26, 2035 · From the USPTO record	In force	Ends no later than May 26, 2035	From the USPTO record

10 of 27 patents shown.

Pro members see all 27.

Pro members: see all 27 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 9 no status recorded

List them